INTRODUCTION {#s1}
============

Lung cancer is still the most common malignancy and is a leading cause of mortality worldwide. In China, Lung cancer had been becoming the most frequently diagnosed cancer (326,600 new cases with an incidence of 50.86/100,000) and the first leading cause of cancer death (with estimated deaths of 569,400) in 2012 \[[@R1]\]. Non-small cell lung cancer accounts for 85% of all lung cancer \[[@R2]\].

Platinum-based double-agent chemotherapy is the first-line therapy for patients with NSCLC \[[@R3]\]. However, for patients harboring active epidermal growth factor receptor (EGFR) mutations, EGFR tyrosine kinase inhibitors (TKIs) therapy may achieve better objective remission rate (ORR) and longer progression free survival(PFS) \[[@R4]\]. NCCN guideline suggested EGFR testing is strongly recommended in NSCLC, EGFR-TKIs are also recommended for NSCLC patients harboring sensitizing EGFR mutation as the first-line treatment \[[@R5]\]. Currently, tumor tissue, which is usually obtained by biopsy or surgery, is the gold standard for detection of EGFR mutations. Unfortunately, most NSCLC patients (70%) are diagnosed at an advanced stage and had no chance to receive surgery. Also, for patients with recurrence disease or acquired resistance to TKIs, repetition of a biopsy is not feasible and will increased discomfort for the patients. Thus, it is difficult to obtain sufficient tumor samples, and circulating-free tumor DNA (cftDNA) have emerged as an noninvasive and replicable method that could provide the same genetic information as a tissue biopsy. It could also be performed at any time during the course of therapy allowing for dynamic monitoring of molecular change \[[@R6]\].

Yunnan province, a region located in the Yunnan-Guizhou Plateau in southwestern China, with an average altitude of 2 kilometers. The natural geographical environment in Yunnan province is complicated and the subtropical mountainous and plateau areas accounts for 94% of Yunnan\'s total land territory (390,000km^2^). The total population of Yunnan includes 46 million people and consists of consisted of multi-ethnic groups including Yi (11%), Hani (3.5%), Bai (3.4%), Dai (2.6%), Zhuang (2.6%) and others (national census in 2011). Xuanwei City located in late Permian coal-accumulating areas in the eastern regions of Yunnan province. The incidence and mortality rate of lung cancer is the highest in China \[[@R7], [@R8]\]. The noticeable features of lung cancer in Xuanwei were: (1) the incidence and mortality rate of lung cancer in female was rather high and almost all of them did not smoke; (2) the major type of lung cancer in women was adenocarcinoma \[[@R9]\]. Previous studies indicated Xuanwei is located in late Permian coal-accumulating areas where is rich for bituminous (smoky) coal. The main cause of high incidence and mortality of lung cancer is indoor air pollution caused by the use of "smoky coal", which releases carcinogenic substances such as polycyclic aromatic hydrocarbons (PAHs), particulate matter and crystalline quartz \[[@R7], [@R10], [@R11]\]. As unique environment, ethnic group and certain susceptible population may have certain genetic background. Investigating EGFR mutation profile of NSCLC patients in Yunnan province especially in Xuanwei region is meaningful.

RESULTS {#s2}
=======

Baseline characters of included patients {#s2_1}
----------------------------------------

Four hundred and forty-seven pathologically confirmed NSCLC patients were included in our analysis. Among these patients, 201 (45.0%) were females and 246 (55.0%) were males. The mean age was 58.2 ± 11.33 years, ranging from 27 to 86 years. Two hundred and twelve patients (47.4%) were smokers and the remaining 235 were never-smokers. 35 (7.8%) patients had the family history of malignancy. The most common histology was adenocarcinoma (387, 86.6%), and the remaining were squamous carcinoma (39, 8.7%), adenosquamous carcinoma (6, 1.3%), large cell carcinoma (4, 0.89%), and NSCLC type undetermined in 11 (2.5%) patients. 8 (1.8%) patients had a history of EGFR-TKI treatments. According to 8 regions of Yunnan, 135 were from central region (Kunming, Yuxi), 118 were from east region (Qujing), 31 were from northeast region (Zhaotong), 35 were from southeast (Wenshan), 15 were from south region (Honghe), 48 were from west region (Chuxiong, Dali, Nujiang, Baoshan, Dehong), 41 were from northwest region (Lijiang, Shangri-La), and the remaining 34 were from southwest region (Xishuangbanna, Lincang, Puer). 63 patients were from Xuanwei where the incidence and mortality rate of lung cancer were the highest in China. Han accounted for the most common ethnic group (406, 90.8%), and the remaining were Yi (14, 3.1%), Bai (7, 1.6%), Dai (5, 1.1%), Naxi (3, 0.67%), Hui (4, 0.89%), Buliang (2, 0.45%), Lisu (2, 0.45%) and Tujia (1, 0.22%). 175 patients with tissue (23 were obtain from biopsy, and 152 were obtain from surgical specimen), 16 patients with cytology specimen (pleural fluid) were available for EGFR mutation analysis. For the remaining 256 patient, most of them were stage IV (222, 86.7%) and could not provide sufficient tissue samples for EGFR testing, plasma were obtained for EGFR testing. Table [1](#T1){ref-type="table"} summarized the main baseline characters of included patients.

###### Frequency of EGFR mutation according to clinical characteristics in overall patients

                                     Positive   Negative   *P*                
  ---------------------------------- ---------- ---------- ------ ----- ----- -----------
  **Age**                                                                     0.272
  \< 65                              310        112        36.1   198   64    
  65--75                             105        37         35.2   68    65    
  \> 75                              32         7          21.9   25    78    
  **Sex**                                                                     \< 0.0001
  Male                               246        63         25.6   183   74    
  Female                             201        93         46.3   108   54    
  Smoking                                                                     0.001
  Yes                                212        58         27.4   154   73    
  No                                 235        98         41.7   137   58    
  **Family history of malignancy**                                            0.452
  Yes                                35         13         37.1   22    63    
  No                                 412        143        34.7   269   65    
  **Histology**                                                               \< 0.0001
  AD                                 387        149        38.5   238   62    
  SCC                                39         5          12.8   34    87    
  ADSC                               6          1          16.7   5     83    
  LCC                                4          0          0      4     100   
  NSCLC                              11         1          9.1    10    91    
  **Tumor Site**                                                              0.137
  Left                               203        61         30     142   70    
  Right                              242        94         38.8   148   61    
  Bilateral                          2          1          50     1     50    
  **Region distribution**                                                     0.209
  Central                            135        35         25.9   100   74    
  East                               118        51         43.2   67    57    
  Northeast                          31         12         38.7   19    61    
  Southeast                          35         11         31.4   24    69    
  South                              15         6          40     9     60    
  West                               38         13         34.2   25    66    
  Northwest                          41         14         34.1   27    66    
  Southwest                          34         14         41.2   20    59    
  **Ethnic**                                                                  0.19
  Han                                406        145        35.7   261   64    
  Yi                                 14         5          35.7   9     64    
  Bai                                7          3          42.9   4     57    
  Dai                                5          1          20     4     80    
  Naxi                               3          0          0      3     100   
  Hui                                4          0          0      4     100   
  Buliang                            2          0          2      2     100   
  Lisu                               2          0          2      2     100   
  Tujia                              1          0          1      1     100   
  **Stage**                                                                   0.278
  Ia                                 20         10         50     10    50    
  Ib                                 30         13         43.3   17    57    
  IIa                                10         3          30     7     70    
  IIb                                12         7          58.3   5     42    
  IIIa                               38         11         28.9   27    71    
  IIIb                               34         9          26.5   25    74    
  IV                                 303        103        34     200   66    
  **Brain metastasis**                                                        0.203
  Yes                                64         27         42.2   37    58    
  No                                 383        129        33.7   254   66    
  **Sample type**                                                             0.026
  Tisue                              175        74         42.3   101   58    
  Plasma                             256        76         29.7   180   70    
  Cytology                           16         6          37.5   10    63    
  **Xuanwei origin**                                                          0.157
  Yes                                63         27         42.8   36    57    
  No                                 384        129        33.6   255   66    
  **Total**                          447        156        34.9   291   65    

Note: AD, adenocarcinoma; SCC, squamous-cell carcinoma; ADSC, adenosquamous carcinoma; LCC, large cell carcinoma; NSCLC, non-small-cell lung cancer.

EGFR mutation rates in tissue and plasma for patients who provided both samples {#s2_2}
-------------------------------------------------------------------------------

To explore the feasible and consistency of EGFR mutation detection in cftDNA in our center, 29 patients provided both tissue and plasma were used to analysis the consistency of EGFR mutation detection in cftDNA when compared with tissue. EGFR mutations were detected in 8 (27.6%) tumor tissue samples, of which, three harbored 19del, two harbored L858R and one harbored 20ins. The EGFR mutation status of matched tissue and plasma were concordant for 25 patients (positive *n* = 5, negative *n* = 20, κ coefficient 0.626, *p* = 0.001). The sensitivity of plasma was 67.5% (5/8), the specificity was 95.2% (20/21), the positive predictive value (PPV) was 83% (5/6), and the negative predictive value (NPV) was 87.0 (20/23). Our data suggest that detection of EGFR mutations in cftDNA is relatively sensitive and highly specific in our center.

Incidence of EGFR mutation and its association with demographic and clinical factors {#s2_3}
------------------------------------------------------------------------------------

EGFR mutation frequency and its relationship with clinicopathological parameters in NSCLC patients in Yunnan are similar to other East Asian countries.

The EGFR mutation was detected in 156 NSCLC patients (34.9%). The difference in EGFR mutation rate was found according to sex, smoking status, pathology type and sample type. It seemed that female (*p* \< 0.0001), no smoking (*p* = 0.001), adenocarcinoma (*p* \< 0.0001), and tissue specimen (*p* = 0.026) were associated with higher EGFR mutation. However, no significant association was found in age (*p* = 0.272), family history of malignancy (*p* = 0.452), the site of tumor (0.137), TNM stage (*p* = 0.278), brain metastasis (*p* = 0.203), the distribution of region (*p* = 0.209), ethnic (*p* = 0.190) and Xuanwei origin (*p* = 0.157).

Incidence of EGFR mutation in tissue, plasma and adenocarcinoma subgroups {#s2_4}
-------------------------------------------------------------------------

Subgroup analysis suggested although the overall mutation rate is different in tissue, plasma and adenocarcinoma subgroups, the relationship between EGFR mutations and clinicopathological parameters was similar.

As sample type maybe a confounding factor for EGFR detecting, we investigated the Incidence of EGFR mutation in tissue and plasma groups respectively. The EGFR mutation rate was 42.3% (74/175), 29.7% (76/256) in tissue and plasma respectively. In tissue subgroups, younger age (\< 65 year) (*p* \< 0.001), female (*p* \< 0.001), no smoking status (*p* \< 0.001), and adenocarcinoma (*p* \< 0.001) was correlated with higher EGFR mutation rate. Also, distribution of region (*p* = 0.007), Xuanwei origin (*p* = 0.007) also had an impact in EGFR mutation rate. In plasma subgroup, we found female (*p* \< 0.001), no smoking (*p* = 0.01) and adenocarcinoma (*p* = 0.042) was associated with higher EGFR mutation rates (Table [2](#T2){ref-type="table"}).

###### Frequency of EGFR mutation in tissue and plasma subgroups

                                   Tissue                             Plasma                                  
  --------------------- ---------- ---------- ------ ----- ---------- ----------- ----- ---- ----- ----- ---- -----------
                        Positive   Negative                Positive   Negative                                
  N                     N          \%         N      \%    P          N           N     \%   N     \%    P    
  Age                                                                 \< 0.0001                               0.27
  \< 65                 122        58         47.5   64    52.5                   177   50   28    127   72   
  65--75                44         16         36.4   28    63.6                   57    20   35    37    65   
  \> 75                 9          0          0      9     100                    22    6    27    16    73   
  Sex                                                                 \< 0.0001                               \< 0.0001
  Male                  93         26         28     67    72                     142   33   23    109   77   
  Female                82         48         58.5   34    41.5                   114   43   38    71    62   
  Smoking                                                             0                                       0
  Yes                   82         24         29.3   58    70.7                   121   31   26    90    74   
  No                    93         50         53.8   43    46.8                   135   45   33    90    67   
  Family history                                                      0.85                                    0.45
  Yes                   15         6          40     9     57.1                   19    7    37    12    63   
  No                    160        68         42.5   92    57.5                   237   69   29    168   71   
  Histology                                                           \< 0.0001                               0.04
  AD                    147        71         48.3   76    51.7                   331   73   32    158   68   
  non-AD                28         3          10.7   25    89.3                   25    3    12    22    88   
  Tumor site                                                          0.44                                    0.14
  Left                  84         33         39.3   51    60.7                   112   26   23    86    77   
  Right                 91         41         45.1   50    54.9                   143   49   34    94    66   
  Bilateral                                                                       1     1    100   0     0    
  Region distribution                                                 0.01                                    0.96
  Central               56         14         25     42    75                     71    18   25    53    75   
  East                  47         29         61.7   18    38.3                   69    20   29    49    71   
  Northeast             12         7          58.3   5     41.7                   19    5    26    14    74   
  Southeast             14         4          28.6   10    71.4                   20    6    30    14    70   
  South                 5          3          60     2     40                     10    3    30    7     70   
  West                  14         5          35.7   9     64.3                   22    8    36    14    64   
  Northwest             17         6          35.3   11    64.7                   23    8    35    15    65   
  Southwest             10         6          60     4     40                     22    8    36    14    64   
  Ethnic                                                              0.31                                    0.73
  Han                   160        70         43.8   90    56.3                   231   70   30    161   70   
  non-Han               15         4          26.7   11    73.3                   25    6    24    19    76   
  Stage                                                               0.79                                    0.44
  I-IIIa                99         45         50     57    50                     10    2    20    8     80   
  IIIb-IV               76         32         42.4   44    57.6                   246   74   31    172   69   
  Brain metastasis                                                    0.14                                    0.2
  Yes                   21         12         57.1   9     42.9                   43    15   35    28    65   
  No                    154        62         40.3   92    59.7                   213   61   29    152   71   
  Xuanwei origin                                                      0                                       0.16
  Yes                   28         19         67.8   9     32.2                   35    8    23    27    77   
  No                    147        55         37.4   92    62.6                   221   68   31    153   69   
  Total                 175        74         42.3   101   57.7                   256   76   30    180        70.3

We also analyzed the frequency of EGFR mutation in adenocarcinoma subgroup. The incidence of EGFR mutation was 38.5% (149/387) in adenocarcinoma. Female (*p* = 0.001), no smoking status (*p* = 0.016), and tissue specimen (*p* = 0.006) may associated with higher EGFR mutation rate (Table [3](#T3){ref-type="table"}).

###### Frequency of EGFR mutation in adenocarcinoma

                                           Positive   Negative   *P*          
  ---------------------------------- ----- ---------- ---------- ----- ------ -------
  Age                                                                         0.61
  \< 65                              276   107        38.3       169   61     
  65--75                             87    35         40.2       52    60     
  \> 75                              24    7          29.2       17    71     
  **Sex**                                                                     0.001
  Male                               200   61         30.5       139   70     
  Female                             187   88         47.1       99    53     
  **Smoking**                                                                 0.016
  Yes                                170   54         31.8       116   68     
  No                                 217   95         43.8       122   56     
  **Family history of malignancy**                                            0.98
  Yes                                31    12         38.7       19    61     
  No                                 356   137        38.5       219   62     
  **Tumor Site**                                                              0.284
  Left                               170   58         34.1       112   66     
  Right                              215   90         41.9       125   58     
  Bilateral                          2     1          50         1     50     
  **Region distribution**                                                     0.095
  Central                            110   33         30         77    70     
  East                               110   50         45.5       60    55     
  Northeast                          28    11         39.3       17    61     
  Southeast                          28    11         39.3       17    61     
  South                              14    6          42.9       8     57     
  West                               32    12         37.5       20    63     
  Northwest                          36    13         36.1       23    64     
  Southwest                          29    13         44.8       16    55     
  **Ethnic**                                                                  0.131
  Han                                353   140        39.7       213   60     
  non-Han                            34    9          26.5       25    74     
  **Stage**                                                                   0.124
  I-IIIa                             88    42         55.6       46    44     
  IIIb-IV                            299   107        36.8       192   63     
  **Brain metastasis**                                                        0.314
  Yes                                61    27         44.3       34    56     
  No                                 326   122        37.4       204   63     
  **Sample type**                                                             0.006
  Tissue                             144   70         48.6       74    51     
  Plasma                             228   73         32         155   68     
  Cytology                           15    6          40         9     60     
  **Xuanwei origin**                                                          0.26
  Yes                                60    27         45         33    55     
  No                                 327   122        37.3       205   63     
  **Total**                          387   149        38.5       238   61.5   

Types of EGFR mutation {#s2_5}
----------------------

EGFR mutation pattern in Yunnan province was in accord with other Asian populations. In Xuanwei subgroup, we found the prevalence of EGFR mutation was different from other general population (higher G719X, G719X+S768I, but lower 19 deletion and L858R mutations).

Overall, EGFR mutation was detected in 156 patients. The most common mutations were exon 19 deletion and L858R point mutation, which was observed in 63 (40%) and 46 (30%) patients, respectively. Single mutation was observed in 139 patients (89.1%), and combined mutation was found in 17 patients (11.9%). Among 156 patients, 127 patients (81.4%) harbored sensitizing mutations, 17 patients (10.9%) harbored resistant mutations, and the remaining 12 patients had both sensitizing and resistant mutations. Eight patients harbored single T790M mutation its combined mutations (three patients for T790M, two for S768I+T790M, and three for 19-del+T790M respectively.). Among these patients, four had ever received EGFR-TKI therapy. Other four patients had ever received TKI treatment were wildtype. Except them, the reaming 339 patients had never received TKI treatment before.

We also performed the subgroup analysis to explore whether sample type, Xuanwei origin, sex, and smoking status would affect the distribution of EGFR mutation type. Our analysis indicated that, the EGFR mutation type distribution in Xuanwei origin was different in other population in Yunnan province. It seemed the prevalence of G719X, S768I+T790M, and G719X+S768I mutations were more common in Xuanwei origin than in other population in Yunnan provinces. However, NSCLC patients with Xuanwei origin harbored lower 19-deletion and L858R mutation rate when compared with other population in Yunnan province (Table [4](#T4){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). According to sample type, we found the frequency of 19-deletion in tissue sample was higher than in plasma. No difference was found in the distribution of EGFR mutation type according to sex and smoking status (Table [4](#T4){ref-type="table"}).

###### EGFR mutation type in our analysis

                                                                    Xuanwei   Sample type   Sex   Smoking                                                                                                         
  ----------------------------------------------------- ---- ------ --------- ------------- ----- --------- ----------- ---- ------ -------- ------ ------ ---- ----- ---- ------ ------- ---- ------ ---- ------ -------
                                                             Yes    No                            Tissue    Plasma           Male   Female          Yes    No                                                     
  N                                                     \%   N      \%        N             \%    P         N           \%   N      \%       P      N      \%   N     \%   P      N       \%   N      \%   P      
  Sensitizing mutations                                                                                                                                                                                           
  G719X                                                 11   7.05   6         22.2          5     3.9       0.001       8    11     3        3.8    0.12   6    9.4   5    5.4    0.34    6    9.8    5    5.3    0.276
  19-deletion                                           63   40.4   5         18.5          58    45        0.019       23   31.5   38       47.5   0.04   28   35    35   38     0.58    22   36.1   41   43.2   0.378
  L861Q                                                 4    2.6    1         3.7           3     2.3       0.54        3    4.1    1        1.3    0.35   3    4.7   1    1.1    0.306   3    4.9    1    1.1    0.3
  L858R                                                 46   29.5   3         11.1          43    33.3      0.038       23   31.5   23       28.8   0.71   16   25    30   32.6   0.305   19   31.1   27   28.4   0.813
  G719X, L861Q                                          1    0.6    0         0             1     0.8       0.10        1    1.4    0        0      0.48   0    0     1    1.1    1.00    0    0      1    1.1    1.00
  G719X, L858R                                          1    0.6    1         3.7           0     0         0.173       1    1.4    0        0      0.48   0    0     1    1.1    1.00    0    0      1    1.1    1.00
  19-deletion, L858R                                    1    0.6    0         0             1     0.8       0.10        0    0      1        1.3    1.00   0    0     1    1.1    1.00    0    0      1    1.1    1.00
  Resistance mutations                                                                                                                                                                                            
  T790M                                                 3    1.9    0         0             3     2.3       0.10        1    1.4    2        2.5    1.00   0    0     3    3.3    0.269   1    1.6    2    2.1    1.00
  S768I                                                 7    4.5    3         11.1          4     3.1       0.10        4    5.5    3        3.8    0.71   5    7.8   2    2.2    0.124   4    6.6    3    3.2    0.433
  20-insertion                                          5    3.2    0         0             5     3.9       0.588       2    2.7    2        2.5    1      3    4.7   2    2.2    0.401   3    4.8    2    2.1    0.38
  S768I,T790M                                           2    1.3    2         7.4           0     0         0.029       0    0      2        2.5    0.5    2    31    0    0      0.167   2    3.3    0    0      0.151
  Combination of sensitizing and resistance mutations                                                                                                                                                             
  19-del, T790M                                         3    1.9    0         0             3     2.3       1.00        0    0      3        100    0.25   0    0     3    3.3    0.269   0    0      3    3.2    0.281
  G719X, S768I                                          7    4.5    5         18.4          2     1.6       \< 0.0001   5    6.8    2        2.5    0.26   1    1.6   6    6.5    0.241   1    1.6    6    6.3    0.248
  S768I, L858R                                          1    0.6    0         0             1     0.8       0.10        1    1.4    0        0      0.48   0    0     1    1.1    1.00    0    0      1    1.1    1.00
  L858R, G719X, S768I                                   1    0.6    1         3.7           0     0         0.17        1    1.4    0        0      0.48   0    0     1    1.1    1.00    0    0      1    1.1    1.00

![The EGFR mutation spectrum in (**A**) Xuanwei population, (**B**) non-Xuanwei population, (**C**) overall population\
NSCLC patients in Xuanwei had higher G719X, G719X+S768I, but lower 19 deletion and L858R mutations when compared with non-Xuanwei patients.](oncotarget-08-15023-g001){#F1}

DISCUSSION {#s3}
==========

In the present study, we investigated the prevalence of EGFR mutation rate in Yunnan province, a mountainous and plateau areas consisted of multi-ethnic groups.

EGFR mutation rate and pattern in overall population {#s3_1}
----------------------------------------------------

The EGFR mutation rate was 34.9% and 42.3% among patients with NSCLC and adenocarcinoma, respectively. In tissue sample, the mutation rate was much higher (42.3% for overall NSCLC patients, and 48.6% for adenocarcinoma). The frequency was in the range of other reports in East Asian countries (31%-50%) \[[@R12]--[@R16]\]. Also, female, never-smokers and adenocarcinoma was correlated with higher rate of NSCLC patients was observed in overall and various subgroups in our studies. This was also familiar with other previous studies \[[@R13]--[@R15]\].

In our study, the most frequent mutation patterns of EGFR were 19 deletion and L858R, which was similar to that reported in studies performed in East Asian countries \[[@R12]--[@R15]\]. In our study, the prevalence of T790M mutation was relatively higher than reported \[the mutation rates of single T790M mutation and complex EGFR mutation containing T790M accounted for 1.9% (three patients) and 3.2% (eight patients) among total mutations\]. We supposed two reasons may account for this issue. Firstly, half of these eight patients had ever received TKI treatment, as a result, the secondary T790M mutation may relate to acquired TKIs resistance in these four patients. Besides, our study recruited patients in single center and the sample size was not large enough, so our sample could not better reflect the overall population.

EGFR mutation pattern in Xuanwei {#s3_2}
--------------------------------

Hosgood et al. reported that the incidence of G719X mutations in exon 18 was higher than general population (50% versus 4%), but L858R mutations was lower than general population (14% versus 41%) \[[@R17]\]. The study by Chen et al. suggested that when compared with patients from non-Xuanwei areas, the NSCLC patients from Xuanwei area harbored higher frequency of G719X+S768I in exon 18 and 21 (45.1% versus 4.1%, *p* \< 0.0001), but had lower frequency of 19 deletion (7.8% versus 49.3%, *p* \< 0.0001) \[[@R18]\]. In our study, we found when compared with non-Xuanwei population, NSCLC patients in Xuanwei areas had higher G719X, G719X+S768I mutations, but harbored lower 19 deletion and L858R mutations. Previous positive findings in Xuanwei patients could be repeated by our analysis. Additionally, Previous studies showed rare EGFR mutations (G719X or L861Q) may had shorter overall survival when compared with those harboring "classical" EGFR mutations (19 deletion or L858R) \[[@R19]\]. However, other rare mutations rather than G719X and L861Q would lead to a worse response to EGFR TKIs \[[@R20]--[@R22]\]. We supposed the prognosis of NSCLC patients in Xuanwei harboring EGFR mutation was theoretically not as better as other populations received EGFR-TKIs treatment.

The EGFR mutation spectrum in Xuanwei was different from other population and even different from never smoking female populations in China. Hosgood et al. supposed this difference might be caused by exposing to indoor air pollution from local smoky coal \[[@R17]\]. Burning "smoky coal" would releases high concentration of PAHs. In Xuanwei residents buring "smoky coal", PAH-DNA adducts have also been observed in bronchoalveolar lavage \[[@R23]\]. Cell-line studies suggested PAHs would increase intracellular calcium in human cell lines, thus may lead to EGFR-dependant cell proliferation \[[@R24]\]. Similarly, KRAS and TP53 mutation spectra in nonsmokers in Xuanwei was consistent with an exposure to PAH, but different with those smokers \[[@R25]\]. Salmonella exposed by smoky coal emissions showed similar KRAS and TP53 mutation spectra exposed by PAHs \[[@R26]\]. These results show that mutations in the TP53 and KRAS genes can reflect a specific environmental exposure. As a result, the unique EGFR mutation spectrum in Xuanwei areas might be related to the exposure of air pollution from local smoky coal. However, which component may play the dominating role, PAHs, particulate matter, crystalline quartz, or their interactions? What is the potential mechanism? Further studies are expected.

The feasibility of cftDNA analysis for EGFR mutations detection {#s3_3}
---------------------------------------------------------------

EGFR mutation analysis is necessary for drug prescription purpose and therefore tumor tissue is always required. Unfortunately, biopsies (bronchoscopy and trans-thoracic biopsies) are not well accepted because tumor tissue is not sufficient or adequate for molecular analysis \[[@R27]\]. Also, repetition of a biopsy would bring patients discomfort. cftDNA has emerged as promising candidate for dynamic monitoring of molecular change \[[@R28]\]. To validate cftDNA analysis for EGFR mutations detection, some efforts have been made in comparing the feasibility of cftDNA analysis for EGFR mutations detection with the actual gold standard that is analysis on tissue. A meta-analysis by Qiu et al. included 27 studies involving 3,110 participants. They reported pooled sensitivity and specificity of cftDNA in detecting EGFR mutation were 0.620 (95% CI: 0.513--0.716) and 0.959 (95% CI: 0.929--0.977), respectively and area under the curve (AUC) was 0.91 (95% CI: 0.89--0.94) \[[@R29]\]. In ASSESS trial, 1,311 patients were enrolled with data available on both tissue and plasma samples of 1,162, the concordance was 89.1%, with a sensitivity of 46%, specificity of 97.4%, PPV of 77.7% and NPV of 90.3% \[[@R30]\]. All this evidence is in favor of the high diagnostic accuracy of cftDNA underlying the high specificity and non-invasivity that make it a useful tool for screening. In our study, 29 patients with paired tissue and plasma were available for analysis. The sensitivity was 67.5%, the specificity was 95.2%, the PPV was 83%, and the NPV was 87.0%. However, smaller sample size may lead to bias. Anyway, we successfully detected EGFR mutation in cftDNA in 256 patients. Most of these patients were stage IV (86.7%) and tumor tissues are not sufficient for EGFR mutation analysis. Disease stage was significantly associated with detecting sensitivity. For patients with advanced stage, the sensitivity of EGFR mutation detection by cftDNA was rather higher than in early stage \[[@R31], [@R32]\]. So, we applied EGFR detection in cftDNA in advanced stage was scientifically reasonable.

To avoid bias, we also analyzed the EGFR mutation rate and pattern in tissue and plasma subgroup. And we found except the overall mutation rate in plasma was lower, the distribution pattern of EGFR mutations was similar to tissue group and previous reports. Our center confirmed the feasible of EGFR mutation detection in cftDNA. It would bring a group of patients a huge benefit from targeted mutation identification for whom obtaining tissue sample is sometimes not feasible. Gives the chance of a targeted therapy also in patients who cannot undergo invasive diagnostic procedures, due to comorbidities or the absence of biopsable tumor lesions

Limitations {#s3_4}
-----------

Some issues should be acknowledged.

Firstly, our data could not represent the true prevalence of EGFR mutation in the NSCLC patients in Yunnan provinces. We only collected available data in our center which may lead to a selection bias. In our study, we found most of our patients were from central and east region (56.6%) of Yunnan. Although Yunnan was a multi-ethnic region, Han accounted for 90.8% of our included patients. The sample from other ethnic patient was lacking, which could not reflect the actually genetic background of Yunnan residents. Also, the sample size of our study was not large enough to reflect the overall population.

Besides, cftDNA analysis for EGFR mutations detection could not reflect actually prevalence of EGFR mutation. Detecting EGFR mutation in tumor tissue was gold standard. As we show above, although the specificity of ctfDNA was rather higher, the sensitivity of ctfDNA was 0.620 (95% CI: 0.513--0.716), and even lower in two trial. As a result, the EGFR mutation rate in plasma was rather lower than in tissue. Some patients with truly EGFR mutation may not detected by ctfDNA. In our study, most of sample analyzed were obtained from plasma (57.3%). And the mutation rate was lower than in tissue (29.7% versus 42.3%, *p* = 0.026). This may affected the true prevalence of EGFR mutation. Detecting EGFR mutation in cftDNA cannot totally substitute for a tumor biopsy. The positive results of EGFR mutation status detected in plasma are highly reliable. Due to the high false negative rate in blood samples, the negative results of EGFR mutation status in plasma need further confirmation.

At last, we did not examine EGFR gene amplification or protein of wild-type and activated status in our study. EGFR mutations, gene amplification, and protein expression may not correlate with each other \[[@R33]\]. EGFR mutation is a better predictive marker for TKIs therapy compared to EGFR gene amplification and protein expression \[[@R33], [@R34]\]. Activating mutations of the EGFR may increase the receptor activity even in the absence of protein overexpression \[[@R33]\]. EGFR mutations change the configuration of the kinase to affect the efficacy of TKIs \[[@R35]\]. Detecting EGFR amplification and protein in matching wild-type and activated status may contribute towards better mechanics exploration for lung cancer development in Yunnan.

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4_1}
----------------

Patients with pathologically confirmed NSCLC who visited the Third Affiliated Hospital of Kunming Medical University between August 2015 and July 2016 were enrolled in our study. Eligibility criteria were:1) adults(\> 18 year) who were residents of Yunnan province, 2) histologically or cytologically confirmed NSCLC. Written informed consents were obtained from all included individuals and approval for this study was obtained from the ethical committee of the Third Affiliated Hospital of Kunming Medical University.

DNA extraction {#s4_2}
--------------

Tissue samples were obtained from excision specimens and biopsy specimens (bronchoscopic biopsy, transbronchial lung biopsy, percutaneous needle biopsy, pleural biopsy and biopsy of metastatic sites). Cytology was mainly obtained from pleural fluids. DNA was extracted from tissue and cytology using an AmoyDx tissue/pleural fulid DNA Kit (Amoy Diagnostics, Xiamen, China) according to the manufacturer\'s instructions. Plasma was separated from 10 ml of peripheral blood in EDTA anticoagulant tubes by centrifugation at 3000 rpm for 5 min within 2 h after collection and stored at −80°C until DNA extraction. Plasma DNA was isolated using an AmoyDx Circulating DNA Kit.

Mutational analysis {#s4_3}
-------------------

Extracted DNA from the tissue and plasma samples were used for the detection of EGFR mutation by Human EGFR Gene Mutation Fluorescence Polymerase Chain Reaction (PCR) Diagnostic Kit (Amoy Diagnostics, Xiamen, China). 29 known mutations in EGFR exons 18--21 were analyzed ([Supplementary Table S1](#SD1){ref-type="supplementary-material"}). The Kit was based on amplification refractory mutation system (ARMS) technology. AmoyDx EGFR Mutations Detection Kit (Amoy Diagnostics, Xiamen, China) had been approved for clinical usage by China Food and Drug Administration (CFDA) since 2010.

Statistical analysis {#s4_4}
--------------------

The relationship between EGFR mutation and demographic and clinical factors (such as age, sex, smoking status, histological type, population distribution, ethnic, specimen type, tumor site and whether Xuanwei origin or not, et.al) were analyzed by Pearson Chi-square or Fisher exact test were. All the statistics were performed by SPSS 22.0 (SPSS Inc., Chicago, IL, USA), two-sided *p* \< 0.05 were considered statistically significant.

CONCLUSIONS {#s5}
===========

Overall, the prevalence of EGFR mutation in NSCLC patients in Yunnan province was consistent with other Asian populations. In Xuanwei subgroup, we found the prevalence of EGFR mutation was different from other general population (higher G719X, G719X+S768I, but lower 19 deletion and L858R mutations). Besides, EGFR mutation analysis by cftDNA is feasible and represents one of the most important recent breakthroughs in thoracic oncology. With the limitation of our study, large sample size from multi-center in Yunnan should be included to make it more representative of the overall population. Also, as tumor tissue is gold standard to detect EGFR mutation, it should be collected as possible.

Supplementary data {#s5_1}
------------------

[Supplementary Table 1](#SD1){ref-type="supplementary-material"}. 29 known mutations in EGFR exons 18--21 analyzed in our study.
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